{"title":"[Pulmonary hypertension due to left heart disease].","authors":"Charles Fauvel, Bouchra Lamia, Nicolas Lamblin","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE. Pulmonary hypertension due to left heart disease (PH-LHD) is the leading cause of PH worldwide and is associated with poor short to long-term survival. Its diagnosis (mean pulmonary artery pressure > 20 mmHg with pulmonary artery wedge pressure > 15 mmHg) requires right heart catheterization at rest and afterwards, isolated post-capillary PH (RVP lower 2 WU) has to be separated from combined pre- and post-capillary PH (RVP ≥ 2 WU). Pulmonary vasodilator therapies are not indicated in PH-LHD (grade III) and the main goal is to optimize left heart disease treatment (i.e., heart failure with preserved or reduced ejection fraction or valvular heart disease).</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 1","pages":"50-55"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue du praticien","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE. Pulmonary hypertension due to left heart disease (PH-LHD) is the leading cause of PH worldwide and is associated with poor short to long-term survival. Its diagnosis (mean pulmonary artery pressure > 20 mmHg with pulmonary artery wedge pressure > 15 mmHg) requires right heart catheterization at rest and afterwards, isolated post-capillary PH (RVP lower 2 WU) has to be separated from combined pre- and post-capillary PH (RVP ≥ 2 WU). Pulmonary vasodilator therapies are not indicated in PH-LHD (grade III) and the main goal is to optimize left heart disease treatment (i.e., heart failure with preserved or reduced ejection fraction or valvular heart disease).